959 Safety and anti-tumor activity of TCR-engineered autologous, PRAME-directed T cells across multiple advanced solid cancers at low doses – clinical update on the ACTengine® IMA203 trial
Main Authors: | Harpreet Singh, Jason Luke, Mamta Kalra, Martin Wermke, Dejka Araujo, Ali Mohamed, Winfried Alsdorf, Apostolia-Maria Tsimberidou, Andrea Mayer-Mokler, Arun Satelli, Carsten Reinhardt, Dominik Maurer, George Jr Blumenschein, Kerstin Guenther, Manik Chatterjee, Norbert Hilf, Regina Mendrzyk, Steffen Walter, Stephen Eck, Tobias AW Holderried, Toni Weinschenk, Van Morris, Cedrik M Britten |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2021-11-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Similar Items
-
The use of οἰκονομία for missions in Ephesians
by: Timothy A. van Aarde
Published: (2016-03-01) -
17.959 Organizational Analysis, Fall 2005
by: Sapolsky, Harvey
Published: (2023) -
O IIρωτομαστορας la primera tragedia de Nikos Kazantzakis O IIρωτομαστορας Nikos Kazantzakis' first tragedy
by: OLGA OMATOS SAENZ
Published: (2009-01-01) -
Expression of PRAME gene in multiple myeloma
by: I В Abramenko, et al.
Published: (2004-07-01) -
The expansion of the PRAME gene family in Eutheria.
by: Ti-Cheng Chang, et al.
Published: (2011-01-01)